Sun Pharma acquires Pharmalucence

Sun Pharmaceutical Industries (BSE: 524715), India's third-largest generic drugmaker by sales, revealed that it has today acquired USA-based Pharmalucence, through one of its subsidiaries. Financial terms of the deal were not disclosed.

Pharmalucence, based in New England, is an employee owned manufacturer of human injectable pharmaceuticals and has sterile injectable capacity in the USA, supported by strong R&D capabilities.

The company provides contract and private label formulation development and manufacturing services of non-cytotoxic human injectables in either liquid or lyophilized form. Its new 70,000 sq ft facility is the region's first CMO to utilize fully-automated and isolated aseptic technologyin support of a wide array of customer needs, from small clinical fills up to full commercial scale production for markets worldwide.

Sun Pharma adds to acquisition of Ranbaxy in India

This is the second recent acquisition for Sun Pharma, which, earlier this year,  acquired Ranbaxy Laboratories in an all-stock transaction with a total equity value of $3.2 billion along with debt of $800 million, taking the overall deal value to $4 billion.